Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNE1 | P15382 | 1/20 | 0.36 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3894061 | 0.81 | KCNE1 (0.35) | KCNE1KCNQ1HTTMAOAMAOB | |
| SCHEMBL11317481 | 0.81 | KCNE1 (0.38) | KCNE1KCNQ1HTTMAOAMAOB | |
| SCHEMBL29249349 | 0.80 | CHRNB2 (0.36) | KCNE1KCNQ1HTTMAOAMAOB | |
| Arsenic SCHEMBL8675880 | 0.79 | LMNA (0.34) | KCNE1KCNQ1HTTMAOAMAOB | |
| SCHEMBL17929070 | 0.76 | KCNE1 (0.43) | KCNE1KCNQ1HTTMAOAMAOB | |
| SCHEMBL15254619 | 0.76 | KCNE1 (0.43) | KCNE1KCNQ1HTTMAOAMAOB | |
| SCHEMBL297734 | 0.76 | KCNE1 (0.36) | KCNE1KCNQ1HTTLMNAABCB1 | |
| SCHEMBL15820172 | 0.75 | ATM (0.40) | KCNE1KCNQ1HTTLMNAABCB1 | |
| SCHEMBL3301289 | 0.73 | KCNE1 (0.34) | KCNE1KCNQ1HTTLMNAABCB1 | |
| SCHEMBL10435275 | 0.73 | CHRNB2 (0.36) | KCNE1KCNQ1HTTMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120171156-A1 | METHODS AND COMPOUNDS FOR REDUCING ALLERGIC REACTIONS TO HAIR DYES | HDS LTD. (GB) | 2012-07-05 | — | — | US | claimed |
| EP-2442873-A2 | METHODS AND COMPOUNDS FOR REDUCING ALLERGIC REACTIONS TO HAIR DYES | Hds Limited (GB) | 2012-04-25 | — | — | EP | claimed |
| WO-2010146142-A9 | METHODS AND COMPOUNDS FOR REDUCING ALLERGIC REACTIONS TO HAIR DYES | HDS LIMITED (GB) | 2011-06-16 | — | — | WO | claimed |
| WO-2010146142-A2 | METHODS AND COMPOUNDS FOR REDUCING ALLERGIC REACTIONS TO HAIR DYES | HDS LIMITED (GB) | 2010-12-23 | — | — | WO | claimed |
| WO-2016110872-A1 | FOOT CARE COMPOSITIONS | Zydus Wellness Limited (IN) | 2016-07-14 | — | — | WO | disclosed |
| US-20120171156-A1 | METHODS AND COMPOUNDS FOR REDUCING ALLERGIC REACTIONS TO HAIR DYES | HDS LTD. (GB) | 2012-07-05 | — | — | US | disclosed |
| EP-2442873-A2 | METHODS AND COMPOUNDS FOR REDUCING ALLERGIC REACTIONS TO HAIR DYES | Hds Limited (GB) | 2012-04-25 | — | — | EP | disclosed |
| EP-2337544-A2 | USE OF MATRIX METALLOPROTEINASE INHIBITORS IN SKIN CARE | Living Proof, Inc. (US) | 2011-06-29 | — | — | EP | disclosed |
| EP-1837054-B1 | Cosmetic composition comprising seabuckthorn | PROCTER & GAMBLE (US) | 2011-06-29 | — | — | EP | disclosed |
| WO-2010146142-A9 | METHODS AND COMPOUNDS FOR REDUCING ALLERGIC REACTIONS TO HAIR DYES | HDS LIMITED (GB) | 2011-06-16 | — | — | WO | disclosed |
| WO-2010146142-A2 | METHODS AND COMPOUNDS FOR REDUCING ALLERGIC REACTIONS TO HAIR DYES | HDS LIMITED (GB) | 2010-12-23 | — | — | WO | disclosed |
| US-20100028393-A1 | Cosmetic Composition | THE PROCTER & GAMBLE COMPANY | 2010-02-04 | — | — | US | disclosed |
| WO-2008070368-A2 | METHODS AND COMPOSITIONS FOR SKIN CARE | LIVING PROOF, INC. (US) | 2008-06-12 | — | — | WO | disclosed |
| EP-1839641-A1 | Cosmetic composition comprising botanical extracts and a thickener | The Procter & Gamble Company (US) | 2007-10-03 | — | — | EP | disclosed |
| WO-2007107914-A1 | COSMETIC COMPOSITION COMPRISING GINGKO BILOBA AND SUNSCREEN AGENTS | THE PROCTER & GAMBLE COMPANY (US) | 2007-09-27 | — | — | WO | disclosed |
| US-20070224138-A1 | Cosmetic composition comprising gingko biloba and sunscreen agents | THE PROCTOR & GAMBLE COMPANY | 2007-09-27 | — | — | US | disclosed |
| WO-2007107913-A2 | COSMETIC COMPOSITION COMPRISING SEABUCKTHORN | THE PROCTER & GAMBLE COMPANY (US) | 2007-09-27 | — | — | WO | disclosed |
| US-20070224229-A1 | Cosmetic composition comprising Seabuckthorn | THE PROCTER & GAMBLE COMPANY | 2007-09-27 | — | — | US | disclosed |
| EP-1837054-A1 | Cosmetic composition comprising seabuckthorn | The Procter and Gamble Company (US) | 2007-09-26 | — | — | EP | disclosed |
| EP-1837053-A1 | Cosmetic composition comprising gingko biloba and sunscreen agents | The Procter and Gamble Company (US) | 2007-09-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070224138-A1 | Cosmetic composition comprising gingko biloba and sunscreen agents | DGKB, GLA, DSG1 | KCNE1 2304/4885KCNQ1 2826/4885HTT 1566/4885 |
| US-20100028393-A1 | Cosmetic Composition | CUTA, NONO, TYR | KCNE1 3025/4885KCNQ1 1509/4885HTT 195/4885 |
| US-20070224229-A1 | Cosmetic composition comprising Seabuckthorn | CUTA, DHCR24, AQP3 | KCNE1 1234/4885KCNQ1 214/4885HTT 843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.